


PHARMACEUTICAL 2021



## RELMADA THERAPEUTICS INC. Rank 112 of 402







PHARMACEUTICAL 2021



RELMADA THERAPEUTICS INC. Rank 112 of 402

The relative strengths and weaknesses of RELMADA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RELMADA THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 96% points. The greatest weakness of RELMADA THERAPEUTICS INC. is the variable Net Income, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 187%, being 139% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	118,074
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,603
Liabilities, Non-Current	0
Other Assets	111
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,382
Other Revenues	0
Property and Equipment	1.3
Research and Development	35,973
Selling, General and Administrative Expense	24,866

Output Variable	Value in 1000 USD
Assets	118,186
Liabilities	12,603
Expenses	60,839
Revenues	0
Stockholders Equity	105,583
Net Income	-59,456
Comprehensive Net Income	-59,456
Economic Capital Ratio	187%

